# Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients

> **NCT04248621** · PHASE4 · UNKNOWN · sponsor: **Wonju Severance Christian Hospital** · enrollment: 164 (estimated)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** Leuprorelin
- **DRUG:** Goserelin
- **DRUG:** Triptorelin
- **DRUG:** Degarelix
- **DRUG:** Bicalutamide
- **DRUG:** Flutamide
- **DRUG:** Maximum androgen blockade

## Key facts

- **NCT ID:** NCT04248621
- **Lead sponsor:** Wonju Severance Christian Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-23
- **Primary completion:** 2022-04-30
- **Final completion:** 2022-12-31
- **Target enrollment:** 164 (ESTIMATED)
- **Last updated:** 2021-07-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04248621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04248621, "Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04248621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*